US LNG exports surge but will buyers in China turn up?
DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a micro-cap biotechnology company currently valued at $15.4 million, announced Thursday the launch of a new preeclampsia testing service planned for rollout in Q3 2025 through its New York-based reference laboratory. According to InvestingPro data, the company’s stock has shown strong momentum with a 21% return over the past week, despite facing operational challenges.
The biotechnology company will offer the FDA-cleared PreClara Ratio (sFlt-1/PlGF) biomarker test as part of a strategic collaboration with Thermo Fisher Scientific. The test is designed to aid healthcare providers in assessing the likelihood of progression to severe preeclampsia in hospitalized pregnant women. With an overall Financial Health score of "FAIR" according to InvestingPro, which offers 8 additional key insights about the company, Trinity Biotech is working to strengthen its market position despite current cash flow challenges.
Preeclampsia, a hypertensive disorder affecting approximately 5-8% of pregnancies, impacts around 500,000 women in the United States annually. The condition is characterized by sudden onset high blood pressure and signs of organ dysfunction.
The sFlt-1/PlGF test is intended for use with pregnant women between 23 and 34 weeks gestation who are hospitalized for hypertensive disorders of pregnancy. It must be used alongside other laboratory tests and clinical assessments.
"This launch represents an important strategic milestone in Trinity Biotech’s maternal health strategy," said John Gillard, CEO of Trinity Biotech, according to the company’s press release.
Research published in March 2025 indicated potential neonatal cost savings exceeding $10 million per 1,000 patients when the test is incorporated into standard care, primarily through reduced preterm deliveries and neonatal intensive care unit admissions.
The company stated this launch establishes groundwork for the anticipated commercial introduction of PrePsia, Trinity Biotech’s proprietary preeclampsia risk assessment technology designed for use in early pregnancy.
Trinity Biotech develops, manufactures and markets diagnostic systems for point-of-care and clinical laboratory segments and has recently entered the wearable biosensor industry. With its next earnings report due on August 14, investors following the company’s transformation can access comprehensive analysis through InvestingPro’s detailed Research Report, which provides deep insights into the company’s financial health and growth prospects.
In other recent news, Trinity Biotech has announced that it received approval from the World Health Organization for the offshore manufacturing of its TrinScreen HIV rapid test. This regulatory approval allows the company to transition its production from in-house operations to an outsourced model. The company emphasized that this change will maintain product integrity and regulatory compliance. The approval is a significant step for Trinity Biotech as it aims to streamline its manufacturing processes. This development is part of the company’s broader strategy to optimize its operations. The company did not disclose specific financial impacts of this transition. However, the regulatory approval is expected to support the company’s efforts in maintaining quality while potentially reducing manufacturing costs. This move is one of the latest developments for Trinity Biotech.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.